Children with bad allergies and asthma have a much higher risk of developing cardiovascular problems at a young age, according to research published Tuesday in the Journal of Allergy and Clinical Immunology.Allergies and asthma have already been tied to obesity and other metabolic disorders in adults. The new research suggests the conditions might be more of a public health problem than previously realized.Researchers looked at data on 13,275 children between birth and age 17 in the US and found that asthma and allergies in young children were associated with an increased risk of developing high blood pressure, high cholesterol, and obesity. In addition, eczema, a condition that causes itchy, inflamed skin, was associated with a higher risk of obesity.advertisement Related: Another factor: Children with the most severe cases of asthma and allergies are often treated with steroids. Asthma patients, for example, are often prescribed a drug that falls into the family of beta-agonists, which relax constricted airways and ease breathing. But while they relieve symptoms of asthma, Marshall said, they also can raise blood pressure.“This finding really underscores why we need safer and better long-term medications to treat these disorders,” Silverberg said.Experts said doctors and parents need to be more attuned to cardiovascular problems that crop up in children with asthma and allergies, including checking their cholesterol levels periodically. But they said not enough physicians are doing so.“It hasn’t yet risen to the conscious level of providers that deal with this on a regular basis,” Marshall said, “and that’s alarming.” Megan Thielking Unvaccinated babies not always welcome in pediatricians’ offices On the left is Dulera and on the right is Albuterol, both used for asthma. News Editor Pediatricians urge tough rules on e-cigarettes Tags allergiesasthmapediatrics “If there’s smoke in all these different places, you’ve gotta believe there’s a fire somewhere,” said Dr. Gailen Marshall, an allergy and immunology researcher from the University of Mississippi who was not affiliated with the study. “It’s just a matter of figuring out where the fire’s coming from, and that’s the stage of research we’re in now.”advertisement About the Author Reprints Alan Levine/Flickr @meggophone HealthChildren with allergies, asthma may be at risk of heart problems, too Related: By Megan Thielking Dec. 8, 2015 Reprints [email protected] One possible factor: Children with severe asthma often find it difficult to participate in sports or other physical activity. Kids with severe eczema face a similar problem, because sweat exacerbates their skin condition.These issues can lead to a sedentary lifestyle, and that, in turn, can lead to cardiovascular problems. And there’s no good research on how to keep kids moving when exercise leads to serious side effects like asthma attacks, said Dr. Jonathan Silverberg, a dermatologist at Northwestern University and the lead author of the study. But researchers aren’t sure why the link exists.
Pharmalot About the Author Reprints [email protected] Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. Up and down the ladder: The latest comings and goings What’s included? Log In | Learn More Alex Hogan/STAT STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. @Pharmalot What is it? GET STARTED Hired someone new and exciting? Promoting a rising star? Finally solved that hard-to-fill spot?Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going. Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTED By Ed Silverman Jan. 26, 2018 Reprints Ed Silverman Tags pharmaceuticalsrecruitingSTAT+
Log In | Learn More STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. Alex Hogan/STAT Amgen is probed by Danish regulator after employee posts press release on LinkedIn Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTED Ed Silverman Pharmalot GET STARTED What’s included? About the Author Reprints @Pharmalot Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. By Ed Silverman Feb. 9, 2018 Reprints Tags legalpharmaceuticalspolicySTAT+ [email protected] Anyone who likes to post information about drugs on social media might want to read this: The Danish Medicines Agency is investigating whether an Amgen (AMGN) employee in Denmark violated advertising laws by sharing and liking a U.S. press release about the Kyprolis medication on LinkedIn. If the law was broken, the company may have to pay a penalty and the employee could face up to four months in jail.An agency spokesman declined to provide further details, but explained that advertising prescription medicines to the general public is prohibited. Under Danish law, the general public is defined as anyone who is not a doctor, dentist, veterinarian, pharmacist, nurse, midwife, bioanalyst, clinical dietitian, radiographer, or student in one of these fields. What is it?
GET STARTED STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Daily reporting and analysis The most comprehensive industry coverage from a powerhouse team of reporters Subscriber-only newsletters Daily newsletters to brief you on the most important industry news of the day STAT+ Conversations Weekly opportunities to engage with our reporters and leading industry experts in live video conversations Exclusive industry events Premium access to subscriber-only networking events around the country The best reporters in the industry The most trusted and well-connected newsroom in the health care industry And much more Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr. Log In | Learn More Tags opioidspharmaceuticalsSTAT+ Two major shareholder advisory firms are recommending that AmerisourceBergen (ABC) stockholders support a proposal to require the pharmaceutical wholesaler to report the steps being taken to manage financial and reputational risks associated with the opioid crisis.The firms — Glass Lewis and Institutional Shareholder Services — also recommend shareholders back a proposal to disclose if its board claws back compensation from senior executives due to misconduct and another to split the chief executive and chairman jobs, a move that corporate governance experts often endorse as sound practice. The wholesaler holds its annual shareholder meeting on March 1. Pharmalot Columnist, Senior Writer Ed covers the pharmaceutical industry. What’s included? Advisory firms back proposals requiring AmerisourceBergen to manage opioid risks By Ed Silverman Feb. 14, 2018 Reprints ed.si[email protected] What is it? About the Author Reprints Ed Silverman APStock Pharmalot @Pharmalot Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+. First 30 days free. GET STARTED